I think some of the clinical centers doing covid drug trials must be making buckets of money. Apart from the academic centers, I doubt if they will be doing what they should be - giving priority to the drugs with the best credentials. Money will come into it. If RVX offers $x per patient and BP offers $10x, you can guess the outcome. So the choice of center would be critical. There have been many drug trials, but few new effective drugs, other than antibodies. Why is that?